CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
Sen. Cory Gardner was on campus to learn about CSU's work in testing, senior care facility surveillance and vaccine development.
A team of CSU researchers has entered into an agreement with the Biomedical Advanced Research and Development Authority to further develop a novel process that has the potential to inactivate the SARS-CoV-2 virus.
The research team used existing technologies to treat nine plasma and three whole-blood products.
Using a manufacturing platform developed to prevent the transmission of disease during blood transfusions, IDRC staffers are working with the faculty of several departments at CSU to test an internally developed vaccine candidate dubbed SolaVAX.
Over the last decade, there have been advances in manufacturing and in strategies to rapidly produce a vaccine.
Propelled by the COVID-19 pandemic, a CSU research team is pursuing a vaccine that would thwart the novel coronavirus using a genetically modified form of the well-known probiotic Lactobacillus acidophilus, a bacterium commonly ingested in yogurt and other foods for gut health.
CSU leadership, researchers and alumni are working together to produce hand sanitizer for the campus community.
As the world looks for ways to stop the spread of the new coronavirus, Colorado State University has activated a unique combination of national experts, facilities, and vaccine manufacturing capability to help in the fight.